公开(公告)号：US20170204113A1

公开(公告)日：2017-07-20

申请号：US15107025

申请日：2014-12-23

申请人： PURDUE PHARMA L.P.

发明人： Laykea TAFESSE

IPC分类号： C07D491/08

CPC分类号： C07D491/08 ,  C07D489/12

摘要： The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R1a, R1b, R1c, X, Y, Z, G, O, W1 and W2 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I), and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

公开(公告)号：US20190201410A1

公开(公告)日：2019-07-04

申请号：US16306305

申请日：2017-06-02

申请人： Purdue Pharma L.P.

发明人： Michele HUMMEL ,  Donald J. KYLE ,  Laykea TAFESSE ,  Garth WHITESIDE

IPC分类号： A61K31/5386 ,  A61K31/421 ,  A61K31/455 ,  A61K31/4174 ,  A61K31/402 ,  A61K31/4439 ,  A61K31/5377 ,  A61P25/02

CPC分类号： A61K31/5386 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/402 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/421 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/485 ,  A61K31/5377 ,  A61P25/02

摘要： This application relates to using trace amine associated receptor 1 (TAAR1) agonists and/or partial agonists for treating or preventing pain, especially neuropathic pain.

公开(公告)号：US20170183337A1

公开(公告)日：2017-06-29

申请号：US15455427

申请日：2017-03-10

申请人： Purdue Pharma L.P. ,  Shionogi & Co., Ltd.

发明人： Shigeru ANDO ,  Noriyuki KUROSE ,  Laykea TAFESSE

IPC分类号： C07D417/14

CPC分类号： C07D417/14 ,  A61K31/428 ,  A61K31/496 ,  C07C57/15 ,  C07C59/255 ,  C07C309/29 ,  C07C309/30 ,  C07D417/12

摘要： The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.

公开(公告)号：US20190144400A1

公开(公告)日：2019-05-16

申请号：US16098494

申请日：2017-05-04

申请人： PURDUE PHARMA L.P.

发明人： Paul BLAKE ,  Laykea TAFESSE

IPC分类号： C07D263/28 ,  A61P25/04

摘要： The present disclosure is directed to oxazoline mono- and hetero-pseudodimer compounds, such as compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: These compounds are useful for treating pain. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I) or (II) or a pharmaceutically acceptable salt or solvate thereof.

公开(公告)号：US20160031873A1

公开(公告)日：2016-02-04

申请号：US14776527

申请日：2014-03-13

申请人： PURDUE PHARMA L.P.

发明人： Jiangchao YAO ,  Laykea TAFESSE

IPC分类号： C07D417/12 ,  C07D401/12 ,  C07D405/04 ,  C07D213/81

CPC分类号： C07D417/12 ,  C07D213/30 ,  C07D213/79 ,  C07D213/81 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D409/12

摘要： The present disclosure provides substituted pyridyl-, pyrimidinyl-, pyrazinyl-, pyridazinyl-, and triazinyl-based carboxamides of Formula I-A: R10 Z-HET-E I-A and the pharmaceutically acceptable salts and solvates thereof, wherein Z, HET, R10 and E are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I-A to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

摘要翻译： 本公开内容提供式IA的取代的吡啶基，嘧啶基，吡嗪基 - ，哒嗪基和三嗪基 - 基甲酰胺：其中Z，HET，R10和E 被定义为在说明书中阐述。 本公开还涉及式I-A的化合物用于治疗对钠通道阻断有反应的病症。 本公开的化合物特别可用于治疗疼痛。

公开(公告)号：US20150018366A1

公开(公告)日：2015-01-15

申请号：US14498724

申请日：2014-09-26

申请人： Purdue Pharma L.P.

发明人： Laykea TAFESSE

IPC分类号： C07D417/14 ,  C07D401/14 ,  C07D417/12 ,  C07D401/12 ,  C07D213/61 ,  C07D401/04 ,  C07D407/14

CPC分类号： C07D401/04 ,  C07D213/61 ,  C07D213/72 ,  C07D213/74 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D417/12 ,  C07D417/14

摘要： The invention relates to compounds of formula IA and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.

公开(公告)号：US20140179724A1

公开(公告)日：2014-06-26

申请号：US14105710

申请日：2013-12-13

申请人： Purdue Pharma L.P.

发明人： R. Richard GOEHRING ,  Laykea TAFESSE ,  Mark A. YOUNGMAN

IPC分类号： C07D471/20

CPC分类号： C07D471/10 ,  C07D471/20

摘要： The application is directed to compounds of Formula I′-A especially to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein R1a-R5a, Y, Z are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I′-A, and especially compounds of Formula I-A, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

摘要翻译： 本发明涉及式I'-A化合物，特别是式I-A化合物及其药学上可接受的盐和溶剂合物，其中R1a-R5a，Y，Z如说明书所述定义。 本发明还涉及使用式I'-A化合物，特别是式I-A的化合物来治疗对一种或多种阿片样物质受体或作为合成中间体的调节作用的病症。 本发明的某些化合物特别适用于治疗疼痛。

公开(公告)号：US20220280527A1

公开(公告)日：2022-09-08

申请号：US17569002

申请日：2022-01-05

申请人： Purdue Pharma L.P.

发明人： Michele HUMMEL ,  Donald J. KYLE ,  Laykea TAFESSE ,  Garth WHITESIDE

IPC分类号： A61K31/5386 ,  A61K31/402 ,  A61K31/421 ,  A61K31/4439 ,  A61K31/5377 ,  A61K9/00 ,  A61K31/4164 ,  A61K31/44 ,  A61K31/485 ,  A61P25/02 ,  A61K31/4174 ,  A61K31/455

摘要： This application relates to using trace amine associated receptor 1 (TAARI) agonists and/or partial agonists for treating or preventing pain, especially neuropathic pain.

公开(公告)号：US20140187549A1

公开(公告)日：2014-07-03

申请号：US14105733

申请日：2013-12-13

申请人： Purdue Pharma L.P.

发明人： Laykea TAFESSE

IPC分类号： C07D471/22

CPC分类号： C07D471/08 ,  C07D471/18 ,  C07D471/22 ,  C07D519/00

摘要： The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein , R1a, R3a, R4, Y and Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

摘要翻译： 本申请涉及式I-A化合物及其药学上可接受的盐和溶剂化物，其中R1a，R3a，R4，Y和Za如本说明书所述定义。 本发明还涉及使用式I-A的化合物来治疗对一种或多种阿片样物质受体的调节或作为合成中间体的病症。 本发明的某些化合物特别适用于治疗疼痛。

公开(公告)号：US20130338170A1

公开(公告)日：2013-12-19

申请号：US13852913

申请日：2013-03-28

申请人： Purdue Pharma L.P.

发明人： Laykea TAFESSE

IPC分类号： C07D213/74 ,  C07D401/12 ,  C07D417/14 ,  C07D405/14 ,  C07D401/04 ,  C07D401/14

CPC分类号： C07D401/04 ,  C07D213/61 ,  C07D213/72 ,  C07D213/74 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D417/12 ,  C07D417/14

摘要： The invention relates to compounds of formula IA and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.